NISER

• PhD, University of Heidelberg, Germany (2006)
• M.Tech (Biotech), Center for Biotechnology (CBT), Anna University, Chennai. India (2002)
• B.Pharma,  Tamilnadu Dr. MGR Medical University, Chennai. India (2000)

Pharmaceutical Biology; Structural Bioinformatics; Biotechnology

• Mike Price Fellowship award 2009 jointly sponsored by the European Association for Cancer Research (EACR) and the European CanCer Organization (ECCO).
• Innovative Young Biotechnologist Award (IYBA) 2012, Dept of Biotechnology (DBT), India.
• ABAP young biotechnologist award and Sri Edupuganti Venkataramaiah and Smt.Padmavathi Memorial Gold Medal from Association of Biotechnology and Pharmacy (ABAP) during Sept 2010.
• SAB bioengineer award 2013, Society for Applied Biotechnology (SABT), India.

Publications 

• Behera BP, Naik H, Konkimalla VB. Peptaloid: A Comprehensive Database for Exploring Peptide Alkaloid. J. Chem. Inf. Model. 2024; https://doi.org/10.1021/acs.jcim.4c01667
• Haloi P, Choudhary R, Siva Lokesh B, Konkimalla VB. Dual Drug Nanoparticle Synergistically Induced Apoptosis, Suppressed Inflammation and Protected Autophagic Response in Rheumatoid Arthritis Fibroblast-like Synoviocytes. Immunology Letters. 2024; 267, 106854.
• Roy S, Haloi P, Siva Lokesh B, Chawla S, Konkimalla VB, Jaiswal A. Biocompatible quaternary pullulan functionalized 2D MoS2 glycosheet-based non-leaching and infection-resistant coatings for indwelling medical implants. Journal of Materials Chemistry B. 2023; 202311, 10418 - 10432.
• Singh P, Haloi P, Singh K, Roy S, Sarkar A, Siva Lokesh B, Choudhary R, Mohite C, Chawla S, Konkimalla VB, Sanpui P, Jaiswal A. Palladium Nanocapsules for Photothermal Therapy in the NIR-II Biological Window. ACS Applied Materials & Interfaces. 2023; 15(33), 39081–39098.
• Roy S, Haloi P, Choudhary R, Chawla S, Kumari M, Konkimalla VB, Jaiswal A. Quaternary Pullulan functionalized 2D MoS2 glycosheets:  A potent bactericidal nanoplatform for efficient wound disinfection and healing. ACS Applied Materials & Interfaces.2023; 15(20), 24209–24227.
• Haloi P, Siva Lokesh B, Chawla S, Konkimalla VB. Formulation of a dual drug-loaded nanoparticulate co-delivery hydrogel system and its validation in rheumatoid arthritis animal model. Drug Delivery. 2023; 30(1): 2184307.
• Haloi P, Chawla S and Konkimalla VB. Thermosensitive smart hydrogel of PEITC ameliorates the therapeutic efficacy in Rheumatoid arthritis. European Journal of Pharmaceutical Sciences. 2023: 181: 106367.
• Siva Lokesh B, Haloi P, Konkimalla VB. Fabrication and Optimization of BSA-PEG-loaded Phenethyl Isothiocyanate (PEITC) nanoparticles using Box-Behnken Design for potential application in subcutaneous infection conditions. Journal of Drug Delivery Science and Technology. 2022; 104101.
• Gaikwad M, Konkimalla VB and Salunke-Gawali S. Metal complexes as topoisomerase inhibitors. Inorganica Chimica Acta. 2022; 542: 121089.
• Shinde Y, Patil R, Konkimalla VB, Merugu SB, Mokashi V, Harihar S, Marrot J, Butcher RJ, Salunke-Gawali S. Keto-enol tautomerism of hydroxy naphthoquinone oxime ligands-Copper complexes and topoisomerase inhibition activity. Journal of Molecular Structure. 2022; 1262: 133081
• Roy S, Kumari M, Haloi P, Chawla S, Konkimalla VB, Kumar A, Kashyap HK and Jaiswal A. Quaternary Ammonium Substituted Pullulan Accelerates Wound Healing and Disinfects Staphylococcus aureus Infected Wounds in Mouse Through an Atypical ‘Non-Pore Forming’ Pathway of Bacterial Membrane Disruption. Biomaterials Science. 2022; 10: 581-601.
• Mohanty S, Konkimalla VB, Pal A, Sharma T and Si SC. Naringin as Sustained Delivery Nanoparticles Ameliorates the Anti-inflammatory Activity in a Freund’s Complete Adjuvant-Induced Arthritis Model. ACS Omega. 2021; 6(43): 28630-28641.
• Mohanty S, Sahoo AK, Konkimalla VB, Pal A, and Si SC. Naringin in Combination with Isothiocyanates as Liposomal Formulations Potentiates the Anti-inflammatory Activity in Different Acute and Chronic Animal Models of Rheumatoid Arthritis. ACS Omega. 2020; 5(43): 28319–28332.
• Nayak M, Pradhan A, Giri SS, Samanta M, Konkimalla VB, Saha A. Molecular characterization, tissue distribution and differential nutritional regulation of putative Elovl5 elongase in silver barb (Puntius gonionotus). Comparative Biochemistry and Physiology B. 2018; 217: 27-39.
• Dash TK, Konkimalla VB. Selection of P-Glycoprotein Inhibitor and Formulation of Combinational Nanoformulation Containing Selected Agent Curcumin and DOX for Reversal of Resistance in K562 Cells. Pharmaceutical Research. 2017;34(8):1741-1750. 
• Dash TK, Konkimalla VB. Selection and optimization of nano-formulation of P-glycoprotein inhibitor for reversal of doxorubicin resistance in COLO205 cells. Journal of Pharmacy and Pharmacology. 2017;69(7):834-843.
• Konkimalla VB. An Improved Comparative Docking Approach for Developing Specific Glycogen Phosphorylase Inhibitors Using Pentacyclic Triterpenes. Current Topics in Medicinal Chemistry. 2017;17(14):1640-1645.
• Dash TK, Konkimalla VB. Comparative Study of Different Nano-Formulations of Curcumin for Reversal of Doxorubicin Resistance in K562R Cells. Pharmaceutical Research. 2017;34(2):279-289. 
• Dash TK, Konkimalla VB. Formulation and Optimization of Doxorubicin and Biochanin A Combinational Liposomes for Reversal of Chemoresistance. AAPS PharmSciTech. 2017;18(4):1116-1124. 
• Pal S, Salunke-Gawali S, Konkimalla VB. Induction of Autophagic Cell Death In Apoptosis-Resistant Pancreatic Cancer Cells Using Benzo [α] Phenoxazines Derivatives, 10-Methyl-Benzo [α] Phenoxazine-5-One And Benzo [α] Phenoxazine-5-One. Anti-cancer agents in medicinal chemistry. 2017; 17(1):115-125.
• Patil R, Bhand S, Konkimalla VB, Banerjee P, Ugale B, Chadar D, Saha SK, Praharaj PP, Nagaraja, CM, Chakrovarty D. Molecular association of 2-(n-alkylamino)-1, 4-naphthoquinone derivatives- Electrochemical, DFT studies and antiproliferative activity against leukemia cell lines. Journal of Molecular Structure. 2016; 1125: 272-281.
• Pal S and KonkimallaVB. Sulforaphane regulates phenotypic and functional switching of both induced and spontaneously differentiating human monocytes. International Immunopharmacology. 2016; 35: 85-98.
• Pal S and Konkimalla VB. Data on sulforaphane treatment mediated suppression of autoreactive, inflammatory M1 macrophages. Data in Brief – Supplementary data of publication from International Immunopharmacology 
• Satpathy R, Konkimalla VB, Ratha J. In Silico Based Prediction and Correlation of Dehalogenase Enzyme Activity of Some Haloalkane Compounds by Quantitative Structure Biodegradation Relationship (QSBR) Analysis. Current EnvironmentalEngineering. 2015; 2: 122-126.
• Tripathy R, Mishra D, Konkimalla VB. A novel fuzzy C-means approach for uncovering cholesterol consensus motif from human G-protein coupled receptors (GPCR). Karbala International Journal of Modern Science. 2015; 1(4): 212-224.
• Pal S and KonkimallaVB. Hormetic potential of Sulforaphane (SFN) in switching cells' fate towards survival or death. Mini Rev Med Chem. 2016; 16(12): 980-995.
• Pal S, Konkimalla VB*, Kathwate L, Rao SS, Gejji SP, Puranik V, Weyhermueller T, and Salunke-Gawali S. Targeting chemorefractory COLO205 (BRAF-V600E) cell lines using substituted benzo[a]phenoxazines. RSC Adv. 2015; 5: 82549-82563.
• Satpathy R, Konkimalla VB, Ratha, J. Computer-Aided Design of a Luciferase Like Haloalkane Dehalogenase Enzyme by Homology Based Rational Protein Design (HRPD) Method. Journal of Applied Biotechnology Reports. 2015; 2(4): 315-323.
• Das RP, Konkimalla VB, Rath SN, Hansa J, Jagdeb M. Elucidation of the Molecular Interaction between miRNAs and the HOXA9 Gene, Involved in Acute Myeloid Leukemia, by the Assistance of Argonaute Protein through a Computational Approach. Genomics & Informatics. 2015; 13(2): 45-52.
• Satpathy R, Konkimalla VB, Ratha J. In silico gene co-expression network analysis in Paracoccidioides brasiliensis with reference to haloacid dehalogenase superfamily hydrolase gene. Journal of Pharmacy And Bioallied Sciences. 2015; 7: 212-217.
• Satpathy R, Konkimalla VB, Ratha J. Application of bioinformatics tools and databases in microbial dehalogenation research- A review. Applied Biochemistry and Microbiology. 2015; 51(1): 11-20.
• Jagadeb M, Konkimalla VB, Rath SN, Das RP. Elucidation of the Inhibitory Effect of Phytochemicals with Kir6.2 Wild-Type and Mutant Models Associated in Type-1 Diabetes through Molecular Docking Approach. Genomics & Informatics. 2014; 12(4): 283-288.
• Kathawate L, Joshi PV, Dash TK, Pal S, Nikalje M, Weyhermüller T, Puranik VG, Konkimalla VB and Salunke-Gawali. Reaction between lawsone and aminophenol derivatives- Synthesis, Characterization, Molecular Structures, and Antiproliferative Activity. Journal of Molecular Structure. 2014; 1075: 397-405.
• Shinde Y,  Sproules S, Kathawate L, Pal S,  Konkimalla VB, Salunke-Gawali S. Separation and isolation of tautomers of 2-hydroxy-4-naphthoquinone-1-oxime derivatives by liquid chromatography-Antiproliferative activity and DFT studies. Journal of Chemical Sciences. 2014; 126(1): 213-225.
• Salunke-Gawali S, Pawar O, Nikalje M, Patil R, Weyhermüller T, Puranik VG , Konkimalla VB. Synthesis, characterization, and molecular structures of homologated analogs of 2-bromo-3-(n-alkylamino)-1,4-napthoquinone. Journal of Molecular Structure. 2014; 1056: 97-103.
• Pal S, Jadhav M, Weyhermüller T, Patil Y, Nethaji M, Kasabe U, Kathawate L, Konkimalla VB, Salunke-Gawali S. Molecular structures and antiproliferative activity of side-chain saturated and homologated analogs of 2-chloro-3-(n-alkylamino)-1,4-napthoquinone. Journal of Molecular Structure. 2013; 1049: 355-361.
• Dash TK and Konkimalla VB. Nanoformulations for Delivery of Biomolecules- Focus on Liposomal Variants for siRNA Delivery. Critical reviews in therapeutic drug delivery system. 2013; 30(6): 469-493.
• Dash TK and Konkimalla VB. Polymeric modifications and its implication in drug delivery- Poly-ε-caprolactone (PCL) as a model polymer. Molecular Pharmaceutics. 2012; 9(9): 2365-79. 
• Malwal SR, Dharmarajan S, Perumal Y, Konkimalla VB and Chakrapani H. Design, Synthesis and Evaluation of Thiol-Activated Sources of Sulfur Dioxide (SO₂) as Antimycobacterial Agents. Journal of Medicinal Chemistry. 2012; 55(1): 553-7. 
• Dharmaraja AT, Dash TK, Konkimalla VB and Chakrapani H. Synthesis, Thiol-Mediated Reactive Oxygen Species Generation Profiles and Anti-Proliferative Activities of 2,3-Epoxy-1,4-Naphthoquinones. MedChemComm. 2012; 3: 219-224. 
• Dash TK and Konkimalla VB. Poly-ε-caprolactone based formulations for drug delivery and tissue engineering: a review. Journal of Controlled Release. 2012; 158(1): 15-33. 
• Polier G, Ding J, Konkimalla VB, Eick D, Ribeiro N, Köhler R, Giaisi M, Efferth T, Desaubry L, Krammer PH, Li-Weber M. Wogonin and related natural flavones are inhibitors of CDK9 that induce apoptosis in cancer cells by transcriptional suppression of Mcl-1. Cell Death and Disease. 2011; 2(7): e182. 
• Soomro S, Konkimalla VB, Langenberg T, Mahringer A, Horwedel C, Holenya P, Brand A, Catin C, Fricker G, Dewerchin M, Carmeliet P, Conway EM, Jansen H, Efferth T. Design of novel artemisinin-like derivatives with cytotoxic and anti-angiogenic properties. Journal of Cellular and Molecular Medicine. 2011; 15(5): 1122-1135.
• Sertel S, Fu Y, Zu Y, Rebacz B, Konkimalla VB, Plinkert PK, Krämer A, Gertsch J, Efferth T. Molecular docking and pharmacogenomics of Vinca alkaloids and their monomeric precursors- vindoline and catharanthine. Biochemical Pharmacology. 2011; 81(6): 723-35.
• Youns M, Fu YJ, Zu YG, Kramer A, Konkimalla VB, Radlwimmer B, Sültmann H, Efferth T. Sensitivity and resistance towards isoliquiritigenin, doxorubicin, and methotrexate in T cell acute lymphoblastic leukemia cell lines by pharmacogenomics. Naunyn Schmiedebergs Archives in Pharmacology. 2010; 382(3): 221-34.
• Mahringer A, Karamustafa S, Klotz D, Kahl S, Konkimalla VB, Wang Y, Wang J, Liu H, Boechzelt H, Hao X, Bauer R, Fricker G, Efferth T. Inhibition of P-glycoprotein at the Blood–Brain Barrier by Phytochemicals Derived from Traditional Chinese Medicine. Cancer Genomics Proteomics. 2010; 7: 191-205.
• Konkimalla VB, Efferth T. Inhibition of epidermal growth factor receptor-overexpressing cancer cells by camptothecin, 20-(N, N-diethyl) glycinate. Biochemical Pharmacology. 2010; 80(1): 39-49.
• Konkimalla VB, Blunder M, Bauer R, Efferth T. Inhibition of inducible nitric oxide synthase by bis(helenalinyl)glutarate in RAW264.7 macrophages. Biochemical Pharmacology. 2010;79(11): 1573-1580.
• Ruimi N, Rwashdeh H, Wasser S, Konkimalla VB, Efferth T, Borgatti M, Gambart R, and Mahajna J. Daedalea gibbosa substances inhibit LPS-induced expression of iNOS by suppression of NF-kB and MAPK activities in RAW 264.7 macrophage cells. International Journal of Molecular Medicine. 2010; 25(3): 421-432.
• Konkimalla VB, Efferth T. Inhibition of epidermal growth factor receptor over-expressing cancer cells by the aphorphine-type isoquinoline alkaloid, dicentrine. Biochemical Pharmacology. 2010; 79(8): 1092-9.
• Konkimalla VB, McCubrey JA, and Efferth T. The role of downstream signaling pathways of the epidermal growth factor receptor for artesunate’s activity in cancer cells. Current Cancer Drug Targets. 2009; 9(1): 72-80. 
• Konkimalla VB, Efferth T and Kaina B. Role of Transporter Genes in Cisplatin Resistance. In Vivo. 2008; 22: 279-284.
• Konkimalla VB, Blunder M, Korn B, Soomro SA, Jansen H, Chang W, Posner GH, Bauer R and Efferth T. Effect of artemisinins and other endoperoxides on nitric oxide-related signalling pathway in RAW 264.7 mouse macrophage cells. Nitric Oxide. 2008; 19: 184-191.
• Konkimalla VB, Wang G, Kaina B and Efferth T. Microarray-based Expression of DNA Repair Genes Does not correlate with Growth Inhibition of Cancer Cells by Natural Products Derived from Traditional Chinese Medicine. Cancer Genomics and Proteomics. 2008; 5: 79-84.
• Efferth T, Konkimalla VB, Wang YF, Sauerbrey A, Meinhardt S, Zintl F, Mattern J and Volm M. Prediction of Broad-Spectrum Resistance of Tumors towards Anticancer Drugs`. Clinical Cancer Research. 2008; 14(8): 2405-2412.
• Konkimalla VB and Efferth T. Evidence-Based Chinese Medicine for Cancer Therapy. Journal of Ethnopharmacology. 2008; 116(2): 207-210.
• Konkimalla VB and Efferth T. Anti-cancer natural product library from traditional Chinese medicine. Combinatorial Chemistry and High Throughput Screening. 2008; 11(1): 7-15.
• Kelter G, Steinbach D, Konkimalla VB, Tahara T, Taketani S, Fiebig HH and Efferth T. Role of transferrin receptor and the ABC transporters ABCB6 and ABCB7 for resistance and differentiation of tumor cells towards artesunate. PLoS ONE. 2007; 2(8):  e798.
• Efferth T, Li PC, Konkimalla VB and Kaina B. From traditional Chinese medicine to rational cancer therapy. Trends in Molecular Medicine. 2007; 13(8): 353-361.
• Efferth T, Fu YJ, Zu YG, Schwarz G, Konkimalla VB, and Wink M. Molecular target-guided tumor therapy with natural products derived from traditional Chinese medicine. Current Medicinal Chemistry. 2007; 14(19): 2024-2032.
• Konkimalla VB, Suhas VL, Chandra NR, Gebhart E and Efferth T. Diagnosis and therapy of oral squamous cell carcinoma. Expert Reviews in Anticancer Therapy. 2007; 7(3): 317-329.
• Vinod PK, Konkimalla VB, and Chandra N. In-silico pharmacodynamics-correlation of adverse effects of H2-antihistamines with histamine N-methyl transferase binding potential. Applied Bioinformatics. 2006; 5(3): 141-50.
• Konkimalla VB and Chandra N. Determinants of histamine recognition: implications for the design of antihistamines. Biochemical and Biophysical Research Communications. 2003; 309(2): 425-31.

Book Chapter(s)

• Siva Lokesh B and Konkimalla VB. Novel Strategies for Targeted Nanotherapeutics for cancer control. In: B. Mukherjee (Ed.). Novel Molecular Oncotargets and Nano-oncotherapeutics. Cambridge Scholar Publishing. 2023, pp 395-494. ISBN: 978-1-5275-0713-5.
• Ajmeera S and Konkimalla VB. Nanoformulations to Limit Challenges of Conventional Therapy against Hepatocellular Carcinoma – An Overview. In: B. Mukherjee (Ed.). Nanotherapeutics for the Treatment of Hepatocellular Carcinoma. Bentham Science Publishers. 2022, pp 166-218. ISBN: 978-981-5039-75-7.
• Satpathy R, Konkimalla VB, and Rath J. Fungal Dehalogenation: An Overview. Environmental Biotechnology - Biodegradation, Bioremediation, and Bioconversion of Xenobiotics for Sustainable Development. In:Apple academic press. 2015, pp. 119-132. ISBN: 978-1-771-88362-7
• Dash TK and Konkimalla VB. Modification of Cyclodextrin for Improvement of Complexation and Formulation Properties. In: Handbook of Polymers for Pharmaceutical Technologies: Biodegradable Polymers. Wiley-Scriverner. Vol 3. 2015, pp 205-224. ISBN: 978-1-119-04142-9
• Konkimalla VB. Predicting Cross-Reactivity from Computational Studies for Pre-evaluation of Specific Hepatic Glycogen Phosphorylase Inhibitors. In: Springer. Bioinformatics and Biomedical Engineering. In: Lecture Notes in Computer Science. 2015, 9044, pp 674-682.
• Konkimalla VB, Kramer A, Fu Y and Efferth T. Identification of Molecular Determinants for Cytotoxicity of Isoloquiritigenin from Liquorice (Glycyrrhiza glabra) towards Leukemia Cell Lines. In: Wiley-VCH. Deutsche Forschungsgemeinschaft (DFG) (Ed.), G. Eisenbrand (Ed.). In: Risk Assessment of Phytochemicals in Food: Novel Approaches. 2010, pp 429. ISBN: 978-3-527-32929-8.
• Konkimalla VB and Efferth T. Molecular mechanisms and interactions responsible for radio- and chemoresistance of tumors and their modulation by natural products from Ayurveda. In: R. Arora (Ed.) Herbal Medicine. A cancer chemopreventive and therapeutic perspective. 2010, 7(33). 511-530.

Rational drug discovery and development require a streamlined interdisciplinary effort from researchers working in a specialized area. From active collaboration, the drug discovery process can be and has been significantly shortened by addressing bottlenecks in drug discovery (off-target effects, polypharmacology, and chemoresistance). Our research focuses on some unaddressed questions that could contribute to chemotherapy.

Establishing the bioactivity of a lead molecule (of any origin) from an in vitro study is the start of a long journey in the drug discovery pipeline. The pharmacological effect of the lead molecule observed in vitro may not directly correlate with the in vivo results due to the molecule's physicochemical properties, bio-pharmacokinetics, or structural mimicry. Here, we try to design suitable study models (in silico, in vitro, and/or in vivo) that can progressively help develop a reliable formulation. 

The following are the areas and related publications we presently focus on:

Drug Delivery of Poorly-soluble Phytochemicals

• Haloi P, Siva Lokesh B, Chawla S, Konkimalla VB. Formulation of a dual drug-loaded nanoparticulate co-delivery hydrogel system and its validation in rheumatoid arthritis animal model. Drug Delivery. 2023; 30(1): 2184307.
• Haloi P, Chawla S and Konkimalla VB. Thermosensitive smart hydrogel of PEITC ameliorates the therapeutic efficacy in Rheumatoid arthritis. European Journal of Pharmaceutical Sciences. 2023: 181: 106367. 
• Siva Lokesh B, Haloi P, Konkimalla VB. Fabrication and Optimization of BSA-PEG-loaded Phenethyl Isothiocyanate (PEITC) nanoparticles using Box-Behnken Design for potential application in subcutaneous infection conditions. Journal of Drug Delivery Science and Technology. 2022; 104101.
• Mohanty S, Sahoo AK, Konkimalla VB, Pal A, and Si SC. Naringin in Combination with Isothiocyanates as Liposomal Formulations Potentiates the Anti-inflammatory Activity in Different Acute and Chronic Animal Models of Rheumatoid Arthritis. ACS Omega. 2020; 5(43): 28319–28332.

Interdisciplinary approaches in the development of cancer therapeutics

• Shinde Y, Patil R, Konkimalla VB, Merugu SB, Mokashi V, Harihar S, Marrot J, Butcher RJ, Salunke-Gawali S. Keto-enol tautomerism of hydroxynaphthoquinoneoxime ligands-Copper complexes and topoisomerase inhibition activity. Journal of Molecular Structure. 2022; 1262: 133081
• Dash TK, Konkimalla VB. Selection of P-Glycoprotein Inhibitor and Formulation of Combinational Nanoformulation Containing Selected Agent Curcumin and DOX for Reversal of Resistance in K562 Cells. Pharm Res. 2017;34(8):1741-1750.
• Dash TK, Konkimalla VB. Selection and optimization of nano-formulation of P-glycoprotein inhibitor for reversal of doxorubicin resistance in COLO205 cells. J Pharm Pharmacol. 2017;69(7):834-843.
• Dash TK, Konkimalla VB. Comparative Study of Different Nano-Formulations of Curcumin for Reversal of Doxorubicin Resistance in K562R Cells. Pharmaceutical Research. 2017;34(2):279-289.
• Dash TK, Konkimalla VB. Formulation and Optimization of Doxorubicin and Biochanin A Combinational Liposomes for Reversal of Chemoresistance. AAPS PharmSciTech. 2017;18(4):1116-1124.
• Patil R, Bhand S, Konkimalla VB, Banerjee P, Ugale B, Chadar D, Saha SK, Praharaj PP, Nagaraja, CM, Chakrovarty D. Molecular association of 2-(n-alkylamino)-1, 4-naphthoquinone derivatives: Electrochemical, DFT studies and antiproliferative activity against leukemia cell lines. Journal of Molecular Structure. 2016; 1125,272-281. 
• Pal S, Konkimalla VB*, Kathwate L, Rao SS, Gejji SP, Puranik V, Weyhermueller T, and Salunke-Gawali S. Targeting chemorefractory COLO205 (BRAF-V600E) cell lines using substituted benzo[a]phenoxazines.  RSC Adv. 2015; 5: 82549-82563.

Understanding cellular response to different ligands deriving its implications

• Pal S, Salunke-Gawali S, Konkimalla VB. Induction of Autophagic Cell Death In Apoptosis-Resistant Pancreatic Cancer Cells Using Benzo [α] Phenoxazines Derivatives, 10-Methyl-Benzo [α] Phenoxazine-5-One And Benzo [α] Phenoxazine-5-One. Anti-cancer agents in medicinal chemistry. 2016,
• Pal S and Konkimalla VB. Sulforaphane regulates phenotypic and functional switching of both induced and spontaneously differentiating human monocytes. International Immunopharmacology. 2016; 35:85-98.
• Pal S and Konkimalla VB. Data on sulforaphane treatment mediated suppression of autoreactive, inflammatory M1 macrophages. Data Brief. 2016 Apr 25;7:1560-4. â€“ Supplementary data of publication from International Immunopharmacology
• Pal S and Konkimalla VB. Hormetic potential of Sulforaphane (SFN) in switching cells' fate towards survival or death. Mini Rev Med Chem. 2016;16(12):980-95.

Other Publications

• Roy S, Haloi P, Siva Lokesh B, Chawla S, Konkimalla VB, Jaiswal A. Biocompatible quaternary pullulan functionalized 2D MoS2 glycosheet-based non-leaching and infection-resistant coatings for indwelling medical implants. Journal of Materials Chemistry B. 2023; 202311, 10418 - 10432.
• Singh P, Haloi P, Singh K, Roy S, Sarkar A, Siva Lokesh B, Choudhary R, Mohite C, Chawla S, Konkimalla VB, Sanpui P, Jaiswal A. Palladium Nanocapsules for Photothermal Therapy in the NIR-II Biological Window. ACS Applied Materials & Interfaces. 2023. 15(33), 39081-39098. 
• Roy S, Haloi P, Choudhary R, Chawla S, Kumari M, Konkimalla VB, Jaiswal A. Quaternary Pullulan functionalized 2D MoS₂ glycosheets:  A potent bactericidal nanoplatform for efficient wound disinfection and healing. ACS Applied Materials & Interfaces. 2023; 15(20), 24209–24227.
• Roy S, Kumari M, Haloi P, Chawla S, Konkimalla VB, Kumar A, Kashyap HK and Jaiswal A. Quaternary Ammonium Substituted Pullulan Accelerates Wound Healing and Disinfects Staphylococcus aureus Infected Wounds in Mouse Through an Atypical ‘Non-Pore Forming’ Pathway of Bacterial Membrane Disruption. Biomaterials Science. 2022; 10: 581-601.
• Malwal SR, Dharmarajan S, Perumal Y, Konkimalla VB and Chakrapani H. Design, Synthesis and Evaluation of Thiol-Activated Sources of Sulfur Dioxide (SO₂) as Antimycobacterial Agents. Journal of Medicinal Chemistry. 2012; 55(1):553-7.
• Polier G, Ding J, Konkimalla VB, Eick D, Ribeiro N, Köhler R, Giaisi M, Efferth T, Desaubry L, Krammer PH, Li-Weber M. Wogonin and related natural flavones are inhibitors of CDK9 that induce apoptosis in cancer cells by transcriptional suppression of Mcl-1. Cell Death and Disease. 2011; 2(7):e182.
• Youns M, Fu YJ, Zu YG, Kramer A, Konkimalla VB, Radlwimmer B, Sültmann H, Efferth T. Sensitivity and resistance towards isoliquiritigenin, doxorubicin, and methotrexate in T cell acute lymphoblastic leukemia cell lines by pharmacogenomics. Naunyn Schmiedebergs Archives in Pharmacology. 2010; 382(3):221-34.
• Konkimalla VB, Blunder M, Korn B, Soomro SA, Jansen H, Chang W, Posner GH, Bauer R and Efferth T. Effect of artemisinins and other endoperoxides on nitric oxide-related signaling pathway in RAW 264.7 mouse macrophage cells. Nitric Oxide. 2008; 19:184-191.
• Efferth T, Konkimalla VB, Wang YF, Sauerbrey A, Meinhardt S, Zintl F, Mattern J and Volm M. Prediction of Broad Spectrum Resistance of Tumors towards Anticancer Drugs`. Clinical Cancer Research. 2008; 14(8):2405-2412.
• Kelter G, Steinbach D, Konkimalla VB, Tahara T, Taketani S, Fiebig HH and Efferth T. Role of transferrin receptor and the ABC transporters ABCB6 and ABCB7 for resistance and differentiation of tumor cells towards artesunate. PLoS ONE. 2007; 2(8): e798.
• Konkimalla VB and Chandra N. Determinants of histamine recognition: implications for the design of antihistamines. Biochemical and Biophysical Research Communications. 2003; 309(2):425-31.

Review articles

• Gaikwad M, Konkimalla VB and Salunke-Gawali S. Metal complexes as topoisomerase inhibitors. Inorganica Chimica Acta. 2022; 542: 121089.
• Pal S and Konkimalla VB. Hormetic potential of Sulforaphane (SFN) in switching cells' fate towards survival or death. Mini Rev Med Chem. 2016; 16(12): 980-995.
• Satpathy R, Konkimalla VB, Ratha J. Application of bioinformatics tools and databases in microbial dehalogenation research: A review. Applied Biochemistry and Microbiology. 2015; 51(1):11-20.
• Dash TK and Konkimalla VB. Nanoformulations for Delivery of Biomolecules; Focus on Liposomal Variants for siRNA Delivery. Critical reviews in therapeutic drug delivery system. 2013; 30(6):469-493.
• Dash TK and Konkimalla VB. Polymeric modifications and its implication in drug delivery: Poly-ε-caprolactone (PCL) as a model polymer. Molecular Pharmaceutics. 2012; 9(9):2365-79.
• Dash TK and Konkimalla VB. Poly-ε-caprolactone based formulations for drug delivery and tissue engineering: a review. Journal of Controlled Release. 2011; 21; 158(1): 15-33.
• Konkimalla VB and Efferth T. Evidence-Based Chinese Medicine for Cancer Therapy. Journal of Ethnopharmacology. 2008; 116(2):207-210.
• Efferth T, Li PC, Konkimalla VB and Kaina B. From traditional Chinese medicine to rational cancer therapy. Trends in Molecular Medicine. 2007; 13(8):353-361.
• Efferth T, Fu YJ, Zu YG, Schwarz G, Konkimalla VB, and Wink M. Molecular target-guided tumor therapy with natural products derived from traditional Chinese medicine. Current Medicinal Chemistry. 2007; 14(19):2024-2032.
• Konkimalla VB, Suhas VL, Chandra NR, Gebhart E and Efferth T. Diagnosis and therapy of oral squamous cell carcinoma. Expert Reviews in Anticancer Therapy. 2007; 7(3):317-329.

Book Chapters

• Siva Lokesh B and Konkimalla VB. Novel Strategies for Targeted Nanotherapeutics for cancer control. In: Novel molecular oncotargets and Nano-oncotherapeutics. Cambridge Scholar Publishing. 2022. Accepted.
• Ajmeera S and Konkimalla VB. Nanoformulations to Limit Challenges of Conventional Therapy against Hepatocellular Carcinoma – An Overview. In: Nanotherapeutics for the Treatment of Hepatocellular Carcinoma. Bentham Science Publishers. 2022, pp 166-218.
• Dash TK and Konkimalla VB. Modification of Cyclodextrin for Improvement of Complexation and Formulation Properties. In: Wiley-Scriverner. In: Handbook of Polymers for Pharmaceutical Technologies: Biodegradable Polymers. Vol 3. 2015, pp 205-224. ISBN: 978-1-119-04142-9.
• Konkimalla VB. Predicting Cross-Reactivity from Computational Studies for Pre-evaluation of Specific Hepatic Glycogen Phosphorylase Inhibitors. In: Springer. Bioinformatics and Biomedical Engineering. In: Lecture Notes in Computer Science. 2015, 9044, pp 674-682.
• Konkimalla VB, Kramer A, Fu Y and Efferth T. Identification of Molecular Determinants for Cytotoxicity of Isoloquiritigenin from Liquorice (Glycyrrhiza glabra) towards Leukemia Cell Lines. In: Wiley-VCH. Deutsche Forschungsgemeinschaft (DFG) (Ed.), G. Eisenbrand (Ed.). In: Risk Assessment of Phytochemicals in Food: Novel Approaches. 2010, pp 429. ISBN: 978-3-527-32929-8.
• Konkimalla VB and Efferth T. Molecular mechanisms and interactions responsible for radio- and chemoresistance of tumors and their modulation by natural products from Ayurveda. In: R. Arora (Ed.) Herbal Medicine. A cancer chemopreventive and therapeutic perspective. 2010, 7(33). 511-530.

• Bioinformatics and Computational Biology (Int MSc, Int PhD and PhD)
• Principles of Drug Design (Int MSc)
• Biology II: Cellular and Genetic Basis of Life (Int MSc)
• Biochemistry (Int MSc) 
• Bioinformatics Lab (Int MSc, Int PhD)
• Biology II lab

• Member, Institutional Animal Ethics Committee (IAEC)